Clinigen adds pharmacovigilance capabilities with acquisition of Drug Safety Navigator – QNT Press Release


November 29, 2022

Clinician adds pharmacovigilance capabilities with acquisition of
Drug Safety Navigator

Clinigen Limited (‘Clinigen’ or the ‘Company’), the global pharmaceutical services company, has agreed to acquire Drug Safety Navigator Inc. (‘DSN’), a specialist pharmacovigilance service provider based in the US. This acquisition enables Clinigen to add vital pharmacovigilance capabilities to its leading pharma services offering for pharmaceutical and biotech clients.

Establishing and maintaining effective pharmacovigilance is increasingly challenging in a globally diverse and complex regulatory environment. DSN provides a suite of global pharmacovigilance (‘PV’) services for clients, including adverse event reporting and medical monitoring PV as well as call ups auport centers , for both clinical and post-marketed medical products.

The acquisition is in line with Clinigen’s strategy of further building out its pharma service offering across the medical product lifecycle to drive value for pharmaceutical and biotech clients.

David Bryant, Chief Executive OfficerClinician, said:

The acquisition of Drug safety Navigator represents an important step in expanding our service offering to pharma and biotech companies across the globe and providethe s another touchpoint to engage with us clients along the medicine…

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center